XLO XILIO THERAPEUTICS INC Investor Conferences 8-K Filing 2025 - Investor Update Xilio Therapeutics, Inc. has posted its latest corporate investor presentation on its website and announced initial data from a Phase 2 clinical trial for vilastobart (XTX101) in combination with atezolizumab, which will be presented at the ASCO 2025 Gastrointestinal Cancer Symposium.Get access to all SEC 8-K filings of the XILIO THERAPEUTICS INC